Biodesix

BDSX

Market cap $133M

Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture

Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing

A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations

The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.